Cancer Research Institute of Kanazawa University

　Currently, one in two people will develop cancer, that is, cancer has become a very familiar disease for many people. However, once diagnosed with cancer, not only does the patient have to endure the physical burden of treatment, but the high cost of treatment and the economic toxicity become major issues. Furthermore, the increase in medical expenses due to the aging of cancer patients has become a major social issue, and it is clear that this issue will arise in countries all over the world in the future. We aim to create a society where cancer treatment is more accessible to everyone, and where appropriate treatment can be received anytime, anywhere.
　To solve this problem, we are consciously working on the following: 1) Developing smart molecules with low manufacturing costs, 2) Dramatically reducing side effects, reducing post-chemotherapy care and hospitalization, reducing the burden on patients and medical staff, and 3) Targeting all cancer patients, regardless of molecular target. The anticancer drug we are currently developing is a “small molecule Magic Buillet” that, despite being a small molecule, exhibits tumor selectivity that surpasses antibodies. In this project, we will continue clinical development and work toward developing drugs for new target diseases, especially intractable cancers.